within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AB01_Megestrol;

model Megestrol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 4.1666666666666667e-07,
    adminDuration = 600,
    adminMass = 160 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00025,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Megestrol</td></tr><tr><td>ATC code:</td><td>L02AB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>160</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Megestrol is a synthetic derivative of the hormone progesterone. It is mainly used as an appetite stimulant in conditions such as cachexia or anorexia associated with cancer or AIDS. It has also been used for the treatment of certain hormonally responsive cancers, such as breast and endometrial carcinoma. Megestrol acetate is approved in several countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients following oral administration of megestrol acetate.</p><h4>References</h4><ol><li><p>Kim, YH, et al., &amp; Bae, KS (2015). Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers. <i>Clinical therapeutics</i> 37(2) 439–447. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2014.09.022\">10.1016/j.clinthera.2014.09.022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25450470/\">https://pubmed.ncbi.nlm.nih.gov/25450470</a></p></li><li><p>Post, TM, et al., &amp; de Greef, R (2016). Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation. <i>Contraception</i> 93(2) 133–138. DOI:<a href=\"https://doi.org/10.1016/j.contraception.2015.08.017\">10.1016/j.contraception.2015.08.017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26365792/\">https://pubmed.ncbi.nlm.nih.gov/26365792</a></p></li><li><p>Markman, M, et al., &amp; Belinson, J (2000). Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 6(11) 4201–4204. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11106232/\">https://pubmed.ncbi.nlm.nih.gov/11106232</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L02AB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Megestrol;
